Related Experiment Videos
Combination of epidermal growth factor receptor targeted therapy with radiation therapy for malignant gliomas
Sunil Krishnan1, Ravi D Rao, C David James
1Division of Radiation Oncology, Mayo Clinic and Foundation. 200 First Street, SW, Rochester, MN 55905, USA.
Abstract:
Glioblastoma multiforme (GBM) are extremely aggressive brain tumors characterized by resistance to standard treatment modalities including surgery, radiation therapy and chemotherapy. While radiation therapy is the standard treatment after surgical resection, these tumors invariably recur and are associated with a uniformly dismal prognosis. Cytotoxic chemotherapy has failed to improve on the modest gains conferred by radiation therapy. Our understanding of the molecular events driving gliomagenesis has led to the recognition of frequent alterations in the epidermal growth factor receptor (EGFR) pathway, leading to increased aggressiveness and a poorer prognosis. Based on the importance of EGFR in the development of malignancy in multiple tumor types, several classes of novel therapeutic agents have been developed that specifically target EGFR. This review outlines the relevance of normal and aberrant EGFR signaling in the biology of gliomas, the strategies for inhibiting EGFR activity and the rationale for combining EGFR inhibitors with radiation therapy in the treatment of GBM.
Insights
Glioblastoma multiforme (GBM) is an aggressive brain tumor. Targeting the epidermal growth factor receptor (EGFR) pathway with novel therapies, combined with radiation, shows promise for improved GBM treatment.
Area of Science:
- Neuro-oncology
- Molecular biology
- Cancer therapeutics
Background:
- Glioblastoma multiforme (GBM) is a highly aggressive brain tumor with poor prognosis.
- Standard treatments (surgery, radiation, chemotherapy) show limited efficacy, with frequent tumor recurrence.
- Aberrant signaling in the epidermal growth factor receptor (EGFR) pathway is implicated in GBM aggressiveness.
Purpose of the Study:
- To review the role of normal and aberrant EGFR signaling in glioma biology.
- To outline strategies for inhibiting EGFR activity in GBM.
- To explore the rationale for combining EGFR inhibitors with radiation therapy for GBM treatment.
Main Methods:
- Literature review of studies on EGFR signaling in gliomas.
- Analysis of therapeutic strategies targeting EGFR.
- Evaluation of preclinical and clinical data on combined EGFR inhibition and radiation therapy.
Main Results:
- EGFR pathway alterations are common in GBM and correlate with poor prognosis.
- Several classes of EGFR inhibitors have been developed.
- Combining EGFR inhibitors with radiation therapy is a promising strategy.
Conclusions:
- EGFR signaling plays a critical role in GBM development and progression.
- Targeting EGFR offers a novel therapeutic avenue for GBM.
- Combination therapy with EGFR inhibitors and radiation may improve treatment outcomes for GBM patients.